000156859 001__ 156859
000156859 005__ 20240229123119.0
000156859 0247_ $$2doi$$a10.1158/1055-9965.EPI-19-1477
000156859 0247_ $$2pmid$$apmid:32616494
000156859 0247_ $$2ISSN$$a1055-9965
000156859 0247_ $$2ISSN$$a1538-7755
000156859 0247_ $$2altmetric$$aaltmetric:85105905
000156859 037__ $$aDKFZ-2020-01176
000156859 041__ $$aeng
000156859 082__ $$a610
000156859 1001_ $$aYammine, Sahar$$b0
000156859 245__ $$aDietary and circulating fatty acids and ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition.
000156859 260__ $$aPhiladelphia, Pa.$$bAACR$$c2020
000156859 3367_ $$2DRIVER$$aarticle
000156859 3367_ $$2DataCite$$aOutput Types/Journal article
000156859 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1602762150_3285
000156859 3367_ $$2BibTeX$$aARTICLE
000156859 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000156859 3367_ $$00$$2EndNote$$aJournal Article
000156859 500__ $$a2020 Sep;29(9):1739-1749
000156859 520__ $$aFatty acids impact obesity, estrogens and inflammation, risk factors for ovarian cancer. Few epidemiological studies have investigated the association of fatty acids with ovarian cancer.Within the European Prospective Investigation into Cancer and nutrition, 1,486 incident ovarian cancer cases were identified. Cox Proportional Hazard models with adjustment for ovarian cancer risk factors were used to estimate hazard ratios of ovarian cancer across quintiles of intake of fatty acids. False discovery rate was computed to control for multiple testing. Multivariable conditional logistic regression models were used to estimate odds ratios of ovarian cancer across tertiles of plasma fatty acids among 633 cases and two matched controls in a nested case-control analysis.A positive association was found between ovarian cancer and intake of industrial trans elaidic acid (Hazard Ratio comparing 5th with 1st quintileQ5-Q1=1.29; 95% CI=1.03-1.62; ptrend=0.02, q-value=0.06). Dietary intakes of n-6 linoleic acid (HRQ5-Q1=1.10; 95% CI=1.01-1.21; ptrend=0.03) and n-3 α-linolenic acid (HRQ5-Q1=1.18; 95% CI=1.05-1.34; ptrend=0.007) from deep frying fats were also positively associated with ovarian cancer. Suggestive associations were reported for circulating elaidic (Odds Ratio comparing 3rd with 1st tertileT3-T1 = 1.39; 95% CI=0.99-1.94; ptrend=0.06) and α-linolenic acids (ORT3-T1=1.30; 95% CI=0.98-1.72; ptrend=0.06).Our results suggest that higher intakes and circulating levels of industrial trans elaidic acid, and higher intakes of linoleic acid and α-linolenic acid from deep frying fat, may be associated with greater risk of ovarian cancer.If causal, eliminating industrial trans fatty acids could offer a straightforward public health action for reducing ovarian cancer.
000156859 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000156859 588__ $$aDataset connected to CrossRef, PubMed,
000156859 7001_ $$aHuybrechts, Inge$$b1
000156859 7001_ $$aBiessy, Carine$$b2
000156859 7001_ $$aDossus, Laure$$b3
000156859 7001_ $$aAglago, Elom K$$b4
000156859 7001_ $$00000-0003-1049-6225$$aNaudin, Sabine$$b5
000156859 7001_ $$aFerrari, Pietro$$b6
000156859 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b7
000156859 7001_ $$00000-0003-4385-2097$$aTjonneland, Anne$$b8
000156859 7001_ $$aHansen, Louise$$b9
000156859 7001_ $$aOvervad, Kim$$b10
000156859 7001_ $$00000-0003-2297-3869$$aRomana Mancini, Francesca$$b11
000156859 7001_ $$00000-0002-5956-5693$$aBoutron-Ruault, Marie-Christine$$b12
000156859 7001_ $$00000-0002-4557-3772$$aKvaskoff, Marina$$b13
000156859 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b14$$udkfz
000156859 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b15$$udkfz
000156859 7001_ $$00000-0002-0830-5277$$aSchulze, Matthias B$$b16
000156859 7001_ $$aBoing, Heiner$$b17
000156859 7001_ $$aTrichopoulou, Antonia$$b18
000156859 7001_ $$00000-0002-3275-2026$$aKarakatsani, Anna$$b19
000156859 7001_ $$00000-0003-1441-897X$$aLa Vecchia, Carlo$$b20
000156859 7001_ $$00000-0002-0415-0386$$aBenetou, Vassiliki$$b21
000156859 7001_ $$00000-0002-5758-9069$$aMasala, Giovanna$$b22
000156859 7001_ $$00000-0003-0122-8624$$aKrogh, Vittorio$$b23
000156859 7001_ $$aMattiello, Amalia$$b24
000156859 7001_ $$aMacciotta, Alessandra$$b25
000156859 7001_ $$00000-0002-0031-4152$$aGram, Inger T$$b26
000156859 7001_ $$00000-0003-2476-4251$$aSkeie, Guri$$b27
000156859 7001_ $$aQuiros Garcia, Jose Ramon$$b28
000156859 7001_ $$aAgudo, Antonio$$b29
000156859 7001_ $$aSanchez-Perez, Maria-Jose$$b30
000156859 7001_ $$aChirlaque, Maria-Dolores$$b31
000156859 7001_ $$00000-0001-8434-2013$$aArdanaz, Eva$$b32
000156859 7001_ $$00000-0001-6843-4460$$aGil, Leire$$b33
000156859 7001_ $$00000-0002-1116-5199$$aSartor, Hanna$$b34
000156859 7001_ $$aDrake, Isabel$$b35
000156859 7001_ $$00000-0002-7865-4560$$aIdahl, Annika$$b36
000156859 7001_ $$aLundin, Eva A$$b37
000156859 7001_ $$aAune, Dagfinn$$b38
000156859 7001_ $$aWard, Heather A$$b39
000156859 7001_ $$aMerritt, Melissa A$$b40
000156859 7001_ $$00000-0003-1938-5038$$aAllen, Naomi E$$b41
000156859 7001_ $$aGunter, Marc J$$b42
000156859 7001_ $$aChajes, Veronique$$b43
000156859 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-19-1477$$gp. cebp.1477.2019 -$$n9$$p1739-1749$$tCancer epidemiology, biomarkers & prevention$$v29$$x1538-7755$$y2020
000156859 909CO $$ooai:inrepo02.dkfz.de:156859$$pVDB
000156859 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000156859 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000156859 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000156859 9141_ $$y2020
000156859 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-17
000156859 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-17
000156859 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-17
000156859 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-17
000156859 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-01-17
000156859 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-17
000156859 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-17
000156859 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-17
000156859 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-17
000156859 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-01-17
000156859 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-17
000156859 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2018$$d2020-01-17
000156859 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-17
000156859 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER EPIDEM BIOMAR : 2018$$d2020-01-17
000156859 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000156859 980__ $$ajournal
000156859 980__ $$aVDB
000156859 980__ $$aI:(DE-He78)C020-20160331
000156859 980__ $$aUNRESTRICTED